However, studies have shown that crizotinib has a weak ability to cross the blood-brain barrier, suggesting that first-generation ALK-TKIs might not alter the natural history of NSCLC cells within the central nervous system (CNS) 26. The gene discussed is ALK; the disease is non-small cell lung carcinoma.